Billions of dollars are flowing into cellular rejuvenation, and in 2026 the first therapy designed to reset the age of human cells entered a clinical trial. The science is real and accelerating. The claim that ageing is about to end is not.
The money arrives
Few areas of biotechnology have attracted wealthy backers as conspicuously as longevity. Altos Labs, backed by Jeff Bezos and Yuri Milner among others, was launched with around three billion dollars and a roster of eminent scientists. Retro Biosciences, funded by OpenAI’s Sam Altman, has been valued at about 1.8 billion dollars. In 2026, NewLimit, co-founded by Coinbase chief executive Brian Armstrong, raised 435 million dollars in a Series C round led by Founders Fund, at a valuation of 3.1 billion dollars, after reporting age-reversal effects in human liver cells in the laboratory. It plans its first human trial in 2027.
The scale is striking, but context matters. Funding for longevity companies reached an estimated 8.5 billion dollars in 2024, a small fraction of overall biotech investment, and ageing research still receives far less public funding than diseases such as cancer, many of which are themselves driven by ageing.
The science of rewinding cells
Most of this money is chasing one idea: partial epigenetic reprogramming. In 2006, Shinya Yamanaka showed that four transcription factors could turn adult cells back into embryonic-like stem cells, work that earned him a Nobel Prize. Full reprogramming erases a cell’s identity, which is useless and potentially dangerous in a living body, where it can cause tumours. Partial reprogramming applies the factors briefly, or uses only three of them, aiming to reset the chemical marks on DNA that drift with age without erasing what the cell is.
The underlying hypothesis, championed by Harvard geneticist David Sinclair among others, is that ageing is driven substantially by a loss of epigenetic information rather than by irreversible damage alone. If that information can be restored, aged cells might function like younger ones. In mice, partial reprogramming has restored vision after optic-nerve damage and improved function in several tissues.
The first human test
In January 2026, the US Food and Drug Administration cleared Life Biosciences, co-founded by Sinclair, to begin a Phase 1 trial of ER-100, a gene therapy that briefly expresses three Yamanaka factors in the eye. It is the first partial-reprogramming therapy to enter human testing. The trial targets two optic-nerve diseases, open-angle glaucoma and non-arteritic anterior ischaemic optic neuropathy, and plans to enrol up to 18 participants.
The eye was chosen deliberately. It is small, accessible, partly isolated from the rest of the body and easy to monitor, which limits risk. On 8 October 2026 the company reported interim data: the lowest dose was well tolerated through 56 days in the first three glaucoma patients, and the safety-monitoring board recommended escalating the dose.
That is encouraging, but its limits must be stated plainly. These are company-reported, open-label results from three people. The trial is designed to test safety, not efficacy. It has not shown that vision is restored, let alone that human ageing can be reversed. It does mark the moment that two decades of laboratory work crossed into human medicine.
The sceptics’ case
Many researchers urge caution. In a 2024 analysis in Nature Aging, demographer S. Jay Olshansky and colleagues argued that radical life extension this century is implausible, noting that gains in life expectancy have slowed as populations approach biological limits. Nobel laureate Venki Ramakrishnan has warned that the field mixes genuine promise with considerable hype. Earlier high-profile candidates have stumbled; Unity Biotechnology’s senolytic drug for osteoarthritis failed its Phase II primary endpoint.
Delivering reprogramming factors safely to every tissue in the body, rather than to one eye, is a vastly harder problem. Regulators also have no established pathway for approving a drug that treats ageing itself; trials target specific diseases instead. Measurement is another hurdle: so-called epigenetic clocks can estimate biological age from DNA methylation patterns, but whether turning back such a clock translates into longer or healthier lives has not been demonstrated, and regulators are unlikely to accept a clock reading as a substitute for clinical outcomes.
Why India should pay attention
For India, the relevant goal is not immortality but healthspan, years lived in good health. According to the UNFPA’s India Ageing Report 2023, the share of Indians aged 60 and above is projected to reach about one in five by 2050, roughly 347 million people. Age-related conditions, from diabetes and cardiovascular disease to cataract, glaucoma and dementia, will dominate the country’s health burden.
Therapies emerging from rejuvenation science, if they succeed, are likely to arrive first as treatments for specific age-related diseases, much as ER-100 targets glaucoma. India’s clinical-research infrastructure, its large patient populations and its gene-therapy capacity, demonstrated by recent domestic CAR-T approvals, position it to participate in later-stage trials and eventually in affordable manufacturing. Indian ageing research, including large cohort studies such as the Longitudinal Ageing Study in India, will also be essential for understanding how interventions perform across diverse populations.
The honest answer
Are we on the brink of ending ageing? No. We are at the beginning of testing whether some features of ageing in some cells can be reversed safely in humans. That is a genuine scientific milestone, and it could eventually transform how age-related diseases are treated. But the distance between three well-tolerated glaucoma patients and a longer human lifespan is measured in decades, not quarters, and much of it may never be crossed.
